Evotec to Present at Two Upcoming IR Conferences in November

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will present at the Jefferies 2016 Global Healthcare Conference in London, UK, and at the German Equity Forum 2016, Frankfurt, Germany.

Jefferies 2016 Global Healthcare Conference in London, UK

Date: Thursday, 17 November 2016, 04.00 pm GMT (05.00 pm CET)

Venue: London, UK

Presenter: Enno Spillner, Chief Financial Officer of Evotec AG

The PDF version and the direct link to the webcast of the presentation will be provided at http://www.evotec.com/.

German Equity Forum 2016 in Frankfurt, Germany

Date: Tuesday, 22 November 2016, 10.00 am CET

Venue: Sheraton Frankfurt Airport Hotel and Conference Center, Frankfurt, Germany

Presenters: Dr Werner Lanthaler,

Chief Executive Officer of Evotec AG;

Enno Spillner,

Chief Financial Officer of Evotec AG

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer in the field of tissue fibrosis. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161114005665/en/